CR9695A - Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica. - Google Patents

Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.

Info

Publication number
CR9695A
CR9695A CR9695A CR9695A CR9695A CR 9695 A CR9695 A CR 9695A CR 9695 A CR9695 A CR 9695A CR 9695 A CR9695 A CR 9695A CR 9695 A CR9695 A CR 9695A
Authority
CR
Costa Rica
Prior art keywords
hypnotic agent
action
association
therapeutics
application
Prior art date
Application number
CR9695A
Other languages
English (en)
Inventor
Alain Cuine
Michel Decobert
Dominique Francon
Henry Saunal
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR9695A publication Critical patent/CR9695A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a la asociacion de un agente hipnotico de duracion de accion corta elegido entre un modulador de los receptores GABA-A, una benzodiazepina, una fenotiazina, un derivado de la melatonina y un agonista de los receptores de la melatonina, y de un agente hipnotico de duracion de accion larga elegido entre un modulador de los receptores GABA-A.
CR9695A 2005-08-19 2008-01-28 Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica. CR9695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508643A FR2889811B1 (fr) 2005-08-19 2005-08-19 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Publications (1)

Publication Number Publication Date
CR9695A true CR9695A (es) 2008-02-20

Family

ID=36273351

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9695A CR9695A (es) 2005-08-19 2008-01-28 Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.

Country Status (26)

Country Link
US (2) US20080181943A1 (es)
EP (1) EP1919473B1 (es)
JP (1) JP5215851B2 (es)
KR (1) KR20080039909A (es)
CN (1) CN101267819B (es)
AR (1) AR055123A1 (es)
AU (1) AU2006281334B2 (es)
BR (1) BRPI0614792A2 (es)
CA (1) CA2618212C (es)
CR (1) CR9695A (es)
EA (1) EA014294B1 (es)
EC (1) ECSP088131A (es)
FR (1) FR2889811B1 (es)
HK (1) HK1124541A1 (es)
HN (1) HN2008000278A (es)
IL (1) IL188823A0 (es)
MA (1) MA29766B1 (es)
MX (1) MX2008002275A (es)
NO (1) NO20081250L (es)
NZ (1) NZ565880A (es)
SG (1) SG165316A1 (es)
TN (1) TNSN08027A1 (es)
TW (1) TW200738238A (es)
UA (1) UA93209C2 (es)
WO (1) WO2007020337A1 (es)
ZA (1) ZA200800968B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
WO2009084023A2 (en) * 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EP2365805A1 (en) * 2008-11-13 2011-09-21 Sanofi Method of treating sleep disorders using eplivanserin
FR2938534B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine
WO2010065547A1 (en) * 2008-12-01 2010-06-10 Map Pharmaceuticals, Inc. Inhalation delivery methods and devices
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
AU2010213678B2 (en) 2009-02-13 2015-11-26 Romark Laboratories L.C. Controlled release pharmaceutical formulations of nitazoxanide
EP2255807A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
WO2012109695A1 (en) * 2011-02-16 2012-08-23 Casal Y Galzov Ramon Ernesto Drug compositions for the treatment of insomnia
WO2012170883A1 (en) 2011-06-09 2012-12-13 Discovery Pharma Consulting, Llc Antihistamines combined with dietary supplements for improved health
CN102579383A (zh) * 2012-04-09 2012-07-18 南京正科制药有限公司 右佐匹克隆缓释片
SG10202004858TA (en) * 2014-02-06 2020-06-29 Lan Bo Chen Composition and method for aiding sleep
CN108289849A (zh) 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
CN105596313B (zh) * 2016-02-17 2018-06-29 新乡医学院第一附属医院 一种具有反向药理功能的用于治疗失眠的胶囊制剂
CN105997958B (zh) * 2016-07-12 2019-03-26 中国人民解放军白求恩医务士官学校 一种口腔外用制剂及其制备方法
JP6830156B2 (ja) * 2016-10-31 2021-02-17 ニューリム・ファーマシューティカルズ・リミテッドＮｅｕｒｉｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． メラトニンミニタブレットおよびその製造方法
WO2018121758A1 (zh) * 2016-12-30 2018-07-05 南京明德新药研发股份有限公司 作为egfr抑制的喹唑啉类化合物
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
US20220096401A1 (en) * 2019-02-08 2022-03-31 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
KR20230028244A (ko) 2020-05-20 2023-02-28 썰테고 테라퓨틱스 아이엔씨. 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
CN115919806A (zh) * 2022-12-22 2023-04-07 南京乐韬生物科技有限公司 一种gaba缓释胶囊的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
ATE247967T1 (de) * 1998-06-09 2003-09-15 Takeda Chemical Industries Ltd Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
DK1691811T3 (da) * 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
CN101257907A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
RU2008110498A (ru) * 2005-08-19 2009-09-27 Авентис Фармасьютикалз Инк. (Us) Комбинация снотворного средства и замещенного соединения бис арила и гетероарила и ее терапевтическое применение
RU2008110477A (ru) * 2005-08-19 2009-09-27 Авентис Фармасьютикалз Инк. (Us) Комбинация снотворного и r (+)-а-(2, 3-диметоксифенил)-1-[2-(4-фторфенил)этил]-4-пиперидинметанола и его терапевтическое применение

Also Published As

Publication number Publication date
CN101267819B (zh) 2012-05-30
TNSN08027A1 (en) 2009-07-14
NZ565880A (en) 2011-07-29
FR2889811B1 (fr) 2009-10-09
CN101267819A (zh) 2008-09-17
IL188823A0 (en) 2008-12-29
CA2618212A1 (fr) 2007-02-22
EA200800618A1 (ru) 2008-06-30
SG165316A1 (en) 2010-10-28
NO20081250L (no) 2008-05-13
AU2006281334B2 (en) 2012-10-18
BRPI0614792A2 (pt) 2011-04-12
ECSP088131A (es) 2008-02-20
EP1919473B1 (fr) 2012-12-05
HN2008000278A (es) 2011-03-30
CA2618212C (fr) 2014-03-25
US20080181943A1 (en) 2008-07-31
US20100291204A1 (en) 2010-11-18
AR055123A1 (es) 2007-08-08
UA93209C2 (ru) 2011-01-25
JP5215851B2 (ja) 2013-06-19
EA014294B1 (ru) 2010-10-29
HK1124541A1 (en) 2009-07-17
MA29766B1 (fr) 2008-09-01
JP2009504713A (ja) 2009-02-05
TW200738238A (en) 2007-10-16
ZA200800968B (en) 2009-04-29
FR2889811A1 (fr) 2007-02-23
MX2008002275A (es) 2008-03-27
KR20080039909A (ko) 2008-05-07
WO2007020337A1 (fr) 2007-02-22
EP1919473A1 (fr) 2008-05-14
AU2006281334A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
CR9695A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.
HN2006007884A (es) Derivados de oxiindol
CL2011002036A1 (es) Analogo peptidico doble agonista de los receptores de glp-1 y de glucagon.
DE602004028229D1 (de) Prostaglandin analoge als ep4 rezeptor agonisten
ECSP10010724A (es) Compuestos de isoindol 5-sustituidos
CL2011000423A1 (es) Composicion que comprende un compuesto antagonista del receptor pd-1 y un agente potenciador; metodo para aumentar una respuesta de celulas t en un mamifero y su uso para tratar cancer.
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
PA8845901A1 (es) Combinacion de una insulina y un agonista de glp-1
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
DK1718641T3 (da) Benzimidazolderivat og dets anvendelse som All-receptorantagonist
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
DK1765795T3 (da) Alkynylderivater som modulatorer for metabotropiske glutamatreceptorer
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
DE602005013675D1 (de) Indol-2-carboxamidin-derivate als antagonisten der nmda-rezeptoren
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
MA28580B1 (fr) 3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
CR8931A (es) Benzoxazoles sustituidos con profarmaco como agentes estrogenicos
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
AR056839A1 (es) Metodos para la administracion transdermica de un agonista indol del receptor de serotonina y composiciones transdermicas para usar en los mismos
CL2012001352A1 (es) Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras.
PA8623501A1 (es) Modulares de receptores de androgenos

Legal Events

Date Code Title Description
FC Refusal